In addition, the association between higher expression of CD44 and poor survival in patients with glioma does not seem to affect by study characteristics such as patient ethnicity, sample size, CD44 detection method, CD44 cutoff, HR estimation strategy, univariate or multivariate analysis, or median follow-up durations. This evidence concerns the gene CD44 and central nervous system cancer.